Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Caribou Biosciences, Inc.
University College Cork
Cedars-Sinai Medical Center
Baylor College of Medicine
Cancer Research UK
University of Miami
M.D. Anderson Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Brown University
VA Office of Research and Development
Centre Hospitalier Régional d'Orléans
CellCentric Ltd.
National Institutes of Health Clinical Center (CC)
Sichuan Baili Pharmaceutical Co., Ltd.
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Weill Medical College of Cornell University
Assistance Publique - Hôpitaux de Paris
Azienda USL Reggio Emilia - IRCCS
Northwestern University
Memorial Sloan Kettering Cancer Center
Indapta Therapeutics, INC.
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Pack Health